Percutaneous left atrial appendage closure devices: safety, efficacy, and clinical utility

Martin J Swaans, Lisette IS Wintgens, Arash Alipour,  Benno JWM Rensing, Lucas VA Boersma Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands Abstract: Atrial fibrillation (AF) is the most common arrhythmia treated in the clinical practice...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Swaans MJ, Wintgens LIS, Alipour A, Rensing BJWM, Boersma LVA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Stroke left atrial appendage prevention. Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/ed823a8e7f95473ea469f7adf5ad2ff8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ed823a8e7f95473ea469f7adf5ad2ff8
record_format	dspace
spelling	oai:doaj.org-article:ed823a8e7f95473ea469f7adf5ad2ff82021-12-02T07:45:26ZPercutaneous left atrial appendage closure devices: safety, efficacy, and clinical utility1179-1470https://doaj.org/article/ed823a8e7f95473ea469f7adf5ad2ff82016-09-01T00:00:00Zhttps://www.dovepress.com/percutaneous-left-atrial-appendage-closure-devices-safety-efficacy-and-peer-reviewed-article-MDERhttps://doaj.org/toc/1179-1470Martin J Swaans, Lisette IS Wintgens, Arash Alipour,  Benno JWM Rensing, Lucas VA Boersma Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands Abstract: Atrial fibrillation (AF) is the most common arrhythmia treated in the clinical practice. One of the major complications of AF is a thromboembolic cerebral ischemic event. Up to 20% of all strokes are caused by AF. Thromboembolic cerebral ischemic event in patients with AF occurs due to atrial thrombi, mainly from the left atrial appendage (LAA). Prevention of clot formation with antiplatelet agents and especially oral anticoagulants (vitamin K antagonists or newer oral anticoagulants) has been shown to be effective in reducing the stroke risk in patients with AF but has several drawbacks with (major) bleedings as the most important disadvantage. Therefore, physical elimination of the LAA, which excludes the site of clot formation by surgical or percutaneous techniques, might be a good alternative. In this review, we discuss the safety, efficacy, and clinical utility of the Watchman™ LAA closure device. Keywords: stroke, left atrial appendage, prevention, atrial fibrillationSwaans MJWintgens LISAlipour ARensing BJWMBoersma LVADove Medical PressarticleStrokeleft atrial appendageprevention.Medical technologyR855-855.5ENMedical Devices: Evidence and Research, Vol Volume 9, Pp 309-316 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Stroke left atrial appendage prevention. Medical technology R855-855.5
spellingShingle	Stroke left atrial appendage prevention. Medical technology R855-855.5 Swaans MJ Wintgens LIS Alipour A Rensing BJWM Boersma LVA Percutaneous left atrial appendage closure devices: safety, efficacy, and clinical utility
description	Martin J Swaans, Lisette IS Wintgens, Arash Alipour,  Benno JWM Rensing, Lucas VA Boersma Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands Abstract: Atrial fibrillation (AF) is the most common arrhythmia treated in the clinical practice. One of the major complications of AF is a thromboembolic cerebral ischemic event. Up to 20% of all strokes are caused by AF. Thromboembolic cerebral ischemic event in patients with AF occurs due to atrial thrombi, mainly from the left atrial appendage (LAA). Prevention of clot formation with antiplatelet agents and especially oral anticoagulants (vitamin K antagonists or newer oral anticoagulants) has been shown to be effective in reducing the stroke risk in patients with AF but has several drawbacks with (major) bleedings as the most important disadvantage. Therefore, physical elimination of the LAA, which excludes the site of clot formation by surgical or percutaneous techniques, might be a good alternative. In this review, we discuss the safety, efficacy, and clinical utility of the Watchman™ LAA closure device. Keywords: stroke, left atrial appendage, prevention, atrial fibrillation
format	article
author	Swaans MJ Wintgens LIS Alipour A Rensing BJWM Boersma LVA
author_facet	Swaans MJ Wintgens LIS Alipour A Rensing BJWM Boersma LVA
author_sort	Swaans MJ
title	Percutaneous left atrial appendage closure devices: safety, efficacy, and clinical utility
title_short	Percutaneous left atrial appendage closure devices: safety, efficacy, and clinical utility
title_full	Percutaneous left atrial appendage closure devices: safety, efficacy, and clinical utility
title_fullStr	Percutaneous left atrial appendage closure devices: safety, efficacy, and clinical utility
title_full_unstemmed	Percutaneous left atrial appendage closure devices: safety, efficacy, and clinical utility
title_sort	percutaneous left atrial appendage closure devices: safety, efficacy, and clinical utility
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/ed823a8e7f95473ea469f7adf5ad2ff8
work_keys_str_mv	AT swaansmj percutaneousleftatrialappendageclosuredevicessafetyefficacyandclinicalutility AT wintgenslis percutaneousleftatrialappendageclosuredevicessafetyefficacyandclinicalutility AT alipoura percutaneousleftatrialappendageclosuredevicessafetyefficacyandclinicalutility AT rensingbjwm percutaneousleftatrialappendageclosuredevicessafetyefficacyandclinicalutility AT boersmalva percutaneousleftatrialappendageclosuredevicessafetyefficacyandclinicalutility
_version_	1718399254652780544

Percutaneous left atrial appendage closure devices: safety, efficacy, and clinical utility

Ejemplares similares